Related Experiment Videos
Ascorbic acid inhibits [3H]SCH-23390 binding to striatal dopamine D1 receptors
H L Wiener1, A Lajtha, H Sershen
1Center for Neurochemistry, Nathan S. Kline Institute for Psychiatric Research, Ward's Island, New York 10035.
Journal of Receptor Research
|January 1, 1989
Summary
Ascorbic acid non-competitively inhibits [3H]SCH-23390 binding to dopamine D1 receptors. This effect is reversible and does not alter receptor affinity, impacting the number of available binding sites.
Area of Science:
- Neuropharmacology
- Biochemistry
Background:
- Dopamine D1 receptors play crucial roles in neurological functions.
- Understanding modulators of dopamine D1 receptor binding is essential for neuroscience research.
Purpose of the Study:
- To investigate the effect of ascorbic acid on [3H]SCH-23390 binding to striatal dopamine D1 receptors.
- To characterize the mechanism and reversibility of ascorbic acid's inhibitory action.
Main Methods:
- Radioligand binding assays using [3H]SCH-23390.
- Scatchard analysis to determine binding kinetics (affinity and site number).
- Incubation and washing protocols to assess reversibility.
Main Results:
- Ascorbic acid non-competitively inhibited [3H]SCH-23390 binding to dopamine D1 receptors.
- Maximum inhibition occurred at 0.1 mM ascorbic acid, reducing binding sites by up to 38%.
- Ascorbic acid did not affect receptor affinity and the inhibition was reversible.
Conclusions:
- Ascorbic acid acts as a non-competitive inhibitor of dopamine D1 receptor binding.
- The interaction involves a reduction in the number of available binding sites, not a change in affinity.
- The reversible nature of this inhibition is important for its potential physiological or experimental implications.